View Clinical Trial (Medical Research Study)
Serum and Synovium Protease Inhibitor Levels in Primary and Secondary Osteoarthritic Joints
| City: |
|
Palo Alto |
| State: |
|
California |
| Zip Code: |
|
94304 |
| Conditions: |
|
Osteoarthritis of the Knee - Alpha2 Macroglobulin |
| Purpose: |
|
Osteoarthritis (OA) is the irreversible degeneration of articular cartilage and underlying
bone. It poses a major healthcare problem as it is the leading cause of joint disease and
disability in the United States. It was traditionally thought that OA was a consequence of
aging and joint trauma. However, it is now thought that OA is a result of the interplay of
multiple genetic, biomechanical, and biochemical factors that disrupt the normal homeostasis
of cartilage, bone, and synovium.
OA is classified into two groups, primary and secondary. Primary OA is classically
polyarticular and peripheral while secondary OA can commonly be attributed to a specific
cause, limited to a singular joint, and a result of trauma. It is known as post-traumatic OA
(PTOA). Other causes of secondary OA include congenital disorders, calcium pyrophosphate
dehydrate deposition disease, and other diseases. Regardless of classification, genetic
variation in the normal metabolism of cartilage and bone is thought to play a role in the
progression of OA. Furthermore, the polyarticular presentation of primary idiopathic
osteoarthritis suggests that it may have a stronger genetic component as compared to
secondary OA, indicating a deviation from normal cartilage and bone homeostasis.
Matrix metalloproteinases (MMP) and their inhibitors take part in the metabolism of
cartilage and bone. MMPs are enzymes that catalyze the degradation of elements within joint
spaces while their inhibitors cease this activity. Alpha-2-Macroglobulin (A2M) is a
naturally-occurring plasma glycoprotein that functions throughout multiple tissues and
extracellular spaces as a protease inhibitor but does not normally reach high levels within
the intra-articular joint space. A2M is believed to modulate the systemic inflammatory
response by its ability to bait, trap, and clear various MMPs and cytokines. Concentrated
A2M directly addresses the roles of cytokines and catabolic enzymes known to participate in
the development of osteoarthritis. Cytonics has shown that A2M can inhibit cartilage
degradation in vitro. As the role of MMPs and protease inhibitors have emerged as key
components of OA, the investigation of regulators of MMP has become of interest to elucidate
the pathogenesis and possible novel treatments of OA.
This study aims to measure and correlate the levels of alpha-2-Macroglobulin (A2M) in plasma
and knee joint OA between primary post-traumatic (PTOA) and secondary osteoarthritis groups.
|
| Study Summary: |
|
This is a single institution observational study.
Pre-procedure diagnosis: Based on chart review and consultation with operating surgeon of
subjects undergoing total knee arthroplasty, patients will be grouped into primary or
secondary (PTOA) osteoarthritis groups. Primary osteoarthritis will be identified through
a clinical presentation of generalized osteoarthritis with possible bilateral involvement
and no identifiable trauma or overuse to knee joint. Secondary osteoarthritis will be
identified by history of overuse or trauma to the afflicted knee and a clinical presentation
that in general lacks symmetrical involvement and/or severity, PTOA.
On the date of surgery, both primary and secondary groups will have 2 cc whole blood
collected via venipuncture during placement of intravenous access for anesthesia. No
additional venipuncture is necessary and this study necessitates no
instrumentation/manipulation of patient beyond that of IV access normally obtained
preoperatively. Blood will then be placed in refrigerated storage (2-6 C) until analyzed
for A2M assay.
On the date of surgery, joint aspirate from both primary and secondary groups will be
collected by the operating surgeon during knee arthroplasty. At the time of arthrotomy,
joint fluid that is expressed from surgical site will be harvested and placed into an
eppendorf tube and placed on ice. The study incurs no further risk to the patient and no
further instrumentation/manipulation for synovial fluid harvest that is beyond the risk or
instrumentation/manipulation of the indicated surgical procedure. Joint aspirates will then
be stored until A2M assay.
|
| Criteria: |
|
Inclusion Criteria:
Group 1, Non-traumatic primary OA:
1. Subject scheduled to undergo primary unilateral total knee arthroplasty for primary
osteoarthritis as determined by an orthopedic surgeon
2. Subject is male or female over 45-75 years of age
3. Subject is able to read and understand informed consent form and must subsequently
sign and date consent form
Group 2, Secondary post-traumatic/overuse OA:
1. Subject scheduled to undergo unilateral total knee arthroplasty secondary
osteoarthritis as determined by an orthopedic surgeon, which MUST include either
previous injury or surgery to the operative knee.
2. Subject is male or female 45-75 years of age
3. Subject is able to read and understand informed consent form and must subsequently
sign and date consent form
Exclusion Criteria:
Group 1, Non-traumatic primary OA:
1. History of inflammatory arthritis (e.g. rheumatoid arthritis, ankylosing spondylitis)
2. Indication for surgery other than osteoarthritis
3. Revision total knee arthroplasty
4. Age >75, age <44
5. Unable to read, understand, or sign informed consent form
6. Previous knee infection
7. Congenital disorders of the knee, calcium pyrophosphate dehydrate deposition disease
Group 2, Secondary post-traumatic/overuse OA:
1. History of inflammatory arthritis (e.g. rheumatoid arthritis, ankyolosing
spondylitis)
2. Indication for surgery other than osteoarthritis
3. Age >75, age <44
4. Unable to read, understand, or sign informed consent form
5. Previous knee infection
6. Congenital disorders of the knee, calcium pyrophosphate dehydrate deposition disease
|
| NCT ID: |
|
NCT01613833 |
| Primary Contact: |
|
Principal Investigator
Gaetano Scuderi, MD
Stanford University, Dept. of Orthopedic Surgery
Gaetano Scuderi, MD
Phone: 650-725-5905
Email: scuderimd@aol.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Palo Alto, California 94304
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 20, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|